Zostavax Clinical Efficacy Trials For 50-59 Year-Olds Needed, Cmte. Says

Merck should conduct full efficacy trials for its zoster vaccine Zostavax in adults aged 50-59, not just immunologic bridging studies, FDA's Vaccines & Related Biological Products Advisory Committee recommended at its Dec. 15 meeting